BRIEF-Jazz Pharmaceuticals Provides Update On Zepzelca Phase 3 Trial

Jazz Pharmaceuticals Public Limited Company

Jazz Pharmaceuticals Public Limited Company

JAZZ

0.00

June 12 (Reuters) - Jazz Pharmaceuticals PLC JAZZ.O:

  • JAZZ PHARMACEUTICALS PROVIDES UPDATE ON ZEPZELCA® (LURBINECTEDIN) PHASE 3 LAGOON TRIAL IN SECOND-LINE SMALL CELL LUNG CANCER

  • JAZZ PHARMACEUTICALS - PHASE 3 LAGOON TRIAL OF ZEPZELCA IN SECOND-LINE SCLC DOES NOT MEET PRIMARY ENDPOINT

  • JAZZ PHARMACEUTICALS - NO NEW SAFETY SIGNALS IDENTIFIED FOR ZEPZELCA IN LAGOON TRIAL

  • JAZZ PHARMACEUTICALS - LAGOON TRIAL RESULTS DO NOT IMPACT 2026 GUIDANCE

Source text: ID:nPn8WSdP3a

Further company coverage: JAZZ.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.